To compare the cardiovascular (CV) risk associated with dipeptidyl peptidase-4 (DPP-4) inhibitors relative to sulphonylureas (SUs) and thiazolidinediones (TZDs).
| INTRODUCTION
In the USA, >25% of the population aged ≥65 years has diabetes. 1 Cardiovascular (CV) disease is a leading cause of morbidity and mortality in patients with diabetes, with the risk increasing with age. 2 While improved glycaemic control by antihyperglycaemic drugs reduces microvascular complications, uncertainty remains regarding risk reduction for CV events. International agencies now require a thorough assessment of CV risk in antihyperglycaemic drug development programmes. 3, 4 The dipeptidyl peptidase-4 (DPP-4) inhibitors are relatively new antihyperglycaemic drugs that have been incorporated into diabetes treatment algorithms as second-line therapy since 2011. These drugs have good tolerability, low risk of hypoglycaemia and are weightneutral compared with other second-line drugs. 5 Three randomized placebo-controlled trials (RCTs) have recently evaluated the CV safety of DPP-4 inhibitors (saxagliptin, alogliptin and sitagliptin) in high-risk patients with type 2 diabetes. [6] [7] [8] [9] All 3 found that no increase in the risk of non-fatal myocardial infarction (MI), stroke or death from CV causes was associated with adding a DPP-4 inhibitor agent vs placebo to existing therapy; however, the saxagliptin trial found an increased risk of hospitalization for heart failure (HF), whereas the other 2 trials did not find any association between DPP-4 inhibitor treatment and HF. (CAROLINA), 10 all the completed trials were placebo-controlled, making it difficult to assess the comparative incidence of CV events relative to therapeutic alternatives. Finally, the aforementioned trials recruited high-risk populations, largely patients with a history of CV events.
Observational studies examining CV risk with DPP-4 inhibitors report no increased relative risk of MI and stroke with DPP-4 inhibitors, but the evidence on HF is mixed. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] These studies mainly reported summary relative risk measures but not the absolute risk measures, which may be important to put the issue in context. Further, some studies used a combined pool of non-DPP-4 inhibitor drugs as the comparator, making the results less useful for physicians in making treatment choices. To date, no epidemiological study has compared the incidence of CV events with DPP-4 inhibitors vs clinically relevant comparators in a US population of older adults with a high prevalence of comorbidity and long duration of diabetes, both of which could influence the effects of DPP-4 inhibitors on CV risk.
We therefore compared the relative and absolute risk of CV outcomes among initiators of DPP-4 inhibitors vs relevant oral drug alternatives, sulphonylureas (SUs) and thiazolidinediones (TZDs), using a 20% sample of the Medicare fee-for-service beneficiaries.
Specifically, we examined the risk of non-fatal MI, stroke, hospitalization for HF and a composite outcome including MI, stroke and allcause mortality.
| METHODS

| Study population
We conducted an active-comparator new-user cohort study using a procedures and prescription drugs for each enrollee and has been previously used to study antihyperglycaemic drugs. [23] [24] [25] From this population, we identified 2 new-user activecomparator cohort pairs mimicking a clinical treatment decision 26 :
(1) DPP-4 inhibitor vs SU initiators, who had not been exposed to either DPP-4 inhibitors or SUs in the previous 6 months, and (2) DPP-4 inhibitor vs TZD initiatiors, who had not been exposed to either DPP-4 inhibitors or TZDs in the previous 6 months. Initiation was defined as the first prescription of the drug after a 6-month washout. Prevalent users of the drugs being compared during the washout period were excluded. To increase the probability of identifying second-line diabetes treatment initiators, all patients were required to have at least 1 metformin prescription in the 6 months before drug initiation. Patients were required to have at least 
| Outcomes
The outcomes assessed were non-fatal MI, stroke, hospitalization for HF and all-cause mortality and a composite outcome of non-fatal MI, stroke and all-cause mortality based on the outcome definition in the RCTs. Medicare claims do not include information on causes of death and we could not identify CV death. However, as CV deaths account for >50% of deaths in patients with diabetes, we used all-cause mortality as a proxy. 27, 28 MI was defined using International Classification of Diseases, Ninth Revision (ICD-9) code 410 in the first or second position of the inpatient claims (definition with a positive predictive value of 94% in a Medicare population). 29 Stroke was defined using ICD-9 codes 430, 431, 433.x1, 434.x1 and 436, located in the first position (specificity 95%-97%, sensitivity 74%-90%). 30 Hospitalization for HF was defined using ICD-9 code 428.xx in the primary position, which has a specificity >98% but a very low sensitivity of 21% in a Medicare population. 31 Patients were followed from the second prescription until the earliest of: the outcome of interest; discontinuation; switching to or augmentation with the comparator drug; non-endpoint event (eg, stroke is a non-endpoint event in the analysis of MI); end of enrolment; or December 31, 2013.
| Confounding control and analysis
We used propensity scores to control for measured confounding.
Using baseline variables (comorbidities, demographics, drug use and healthcare use) measured before initiation, we predicted the probability for initiating DPP-4 inhibitors vs SUs and DPP-4 inhibitors vs TZDs for each patient (propensity score) using 2 separate logistic regression models. 32 We then assigned a weight of 1 to DPP-4 inhibitors and a weight of (propensity score/[ 
| Competing risks
Competing risks arise when the occurrence of 1 event precludes the occurrence of other events. In our study of older adults, mortality is a competing event and standard Cox models censoring patients who die yield biased estimates because this type of censoring may be "informative." 36 We therefore used weighted cumulative incidence curves accounting for competing risk by death to estimate the risk, risk differences (RDs) and risk ratios for non-fatal MI, stroke and hospitalizations for HF among initiators of DPP-4 inhibitors vs comparators. 36 We obtained confidence intervals (CIs) by bootstrapping 1000
replicates. We analysed the composite outcome of non-fatal MI, stroke or all-cause mortality using traditional weighted Cox models.
| Subgroup and sensitivity analyses
Analyses were repeated in prespecified subgroups based on CVD history. Several sensitivity analyses were performed. To increase the probability of CV death, we excluded the deaths of patients with codes for metastatic cancer anytime during follow-up. Finally, we repeated all analyses using an intention-to-treat approach, whereby patients were not censored for treatment changes but followed from the second prescription to the earliest of: the outcome; non-endpoint event; end of enrolment; or December 31, 2013.
| RESULTS
For the DPP-4 inhibitor vs SU comparison (Table 1) Table 3 and Figure 1A ). This was mainly driven by death ( Figure S1 ) rather than MI and stroke, for which risks werẽ (Tables S5   and S6 ). In the subgroup with prior CVD, the risks of MI and stroke were slightly higher (~1.3%-2.0% at 1 year), but the magnitude of RD per 100 patients was <1 (Tables S7 and S8 ). No increased risk of hospitalization for HF was observed with DPP-4 inhibitors vs SUs, with a 5-year RD −1.12 (95% CI −2.02, −0.21; Table S9 ).
For DPP-4 inhibitors vs TZDs, based on 1220 composite events among DPP-4 inhibitor initiators and 920 composite events among TZD initiators, the adjusted HR for the composite outcome was 0.95 (95% CI 0.86-1.03; Figure 1B and Table 3 ). The median time on treatment for the DPP-4 inhibitor initiators was 1.08 years and for the TZD initiators it was 1.16 years. The 1-year RD per 100 patients for MI was −0.04 (95% CI −0.27, 0.18) and for stroke it was −0.07 (95% CI −0.25, 0.11; Tables S10 and S11). In the subgroup without prior CVD, the 1-year risks of MI and stroke were <1% for DPP-4 inhibitors and TZDs (Tables S12 and S13 ). In the subgroup with prior CVD, the 1-year risks were slightly higher than 1% for MI and stroke for both DPP-4 inhibitor and TZD initiators (Tables S14 and S15 ), but the RDs at 1 year were <1 per 100 patients. The RD per 100 patients for hospitalization for HF, comparing DPP-4 inhibitors vs TZDs, was between 0 and −1 during the study period (Table S16 and Figure S2 ).
Sensitivity analyses, excluding metastatic cancer deaths from allcause mortality (which accounted for 14%-16% of deaths in all treatment groups) did not change the results (Table S17) . Additional analyses using an intention-to-treat approach did not change the results (Table S18 ).
| DISCUSSION
We found no difference in the short-term risk of the composite CV outcome between second-line diabetes treatment with DPP-4 inhibitors vs TZD over a median treatment duration of 1 year in the present study. The 1-year RDs for MI, stroke and all-cause mortality were all between 0 and −1 per 100 patients, again indicating no difference in risks of these outcomes among DPP-4 inhibitors and TZD initiators.
The apparent decreased risk of the composite CV outcome with DPP-4 inhibitors vs SU is mainly driven by all-cause mortality rather than by MI or stroke, for which the 1-year RDs were very small (<1 All covariates measured during the baseline period before drug initiation.
a Initiation defined as no dispensed prescriptions for DPP-4 inhibitors or SUs during the 6 months before initiation and filling a second prescription of the same drug/drug class within 6 months after the first prescription. All patients were required to have a metformin prescription in the 6 months before initiation.
b Pseudo-population of SU initiators weighted to the distribution of covariates of the DPP-4 inhibitor initiators using the propensity score to balance covariates (and therefore control for confounding). All covariates measured during the baseline period before drug initiation.
a Initiation defined as no dispensed prescriptions for DPP-4 inhibitors or TZDs during the 6 months before initiation and filling a second prescription of the same drug/drug class within 6 months after the first prescription. All patients were required to have a metformin prescription in the 6 months before initiation. For the DPP-4 inhibitor vs TZD analysis patients with diagnosis of HF, cardiomyopathy, hypertensive disease with HF, chronic kidney disease, oedema and use of loop diuretics were excluded.
b Pseudo-population of TZD initiators weighted to the distribution of covariates of the DPP-4 inhibitor initiators using the propensity score to balance covariates (and therefore control for confounding). Initiation defined as no dispensed prescriptions of the drugs being compared during the 6 months before initiation and filling a second prescription of the same drug/drug class within 6 months after the first prescription. All patients were required to have a metformin prescription in the 6 months before initiation. were not estimated. [18] [19] [20] [21] [22] These studies mainly reported summary relative risk measures but not the absolute risks and RDs which may be important to put the issue in context. The present study is the first to examine this question in an older US population, and reports both relative and absolute risks for CV events accounting for the competing risk by death. Taken together the evidence from the present study and the existing literature suggests that there should be no concern about increased CV risk with DPP-4 inhibitors vs other second-line diabetes treatments. Further research is needed to investigate the relative effect of SU on all-cause mortality.
We did not observe an increased risk of hospitalization for HF with DPP-4 inhibitors vs SUs. While the EXAMINE and TECOS trials did not find an increased HF risk with alogliptin and sitagliptin, respectively, the SAVOR-TIMI 53 trial reported a 27% increased risk of hospitalization for HF with saxagliptin vs placebo. Several factors Observational studies examining HF risk with DPP-4 inhibitors using different designs, populations and comparators report mixed results. Two studies reported a reduced rate of HF compared to other anti-hyperglycaemic drugs 11, 15 , 3 studies suggested no difference in effect, 12, 14, 40 while 2 studies reported increased HF risk with DPP-4 inhibitors compared to other antihyperglycaemic drugs. 16, 17 Most of these studies used a heterogeneous comparator of "all other antihyperglycaemic drugs," which makes interpretation of results difficult, particularly in cases where the risks differed greatly depending on the comparator. 13, [15] [16] [17] 40 One study that reported increased HF risk compared sitagliptin initiators to matched controls who were prevalent users of antihyperglycaemic therapy, which could bias the results because prevalent users could possibly be tolerant to other antihyperglycaemic therapy. 17 Some clinical studies, by contrast, have suggested a protective role of DPP-4 inhibitors in the pathogenesis of CHF. 41, 42 Because TZDs are known to be associated with an increased A strength of the present study is its use of a new-user activecomparator cohort design, which is analogous to a head-to-head clinical trial and answers the more relevant question of which second-line treatment to initiate rather than "treatment or not." 43 the absence of clinical measures, it is hard to identify HF using claims data, and our definition of HF hospitalization had near-perfect specificity (which yields unbiased relative risks), but low sensitivity, which will lead to an underestimation of absolute risks. Fourth, because the occurrence of 1 CV event during follow-up might affect the incidence of a subsequent CV event (eg, MI can affect the risk of stroke), we censored patients at non-endpoint CV events. This could theoretically lead to "competing risk" from the non-endpoint event, but such censoring was extremely rare in the study. Fifth, because we required a baseline period to assess covariates in the period before initiation, patients did not become eligible for inclusion in the present until they reached 66 years of age. We did not include the (very small) group of patients who were aged 65 years at initiation because these were a "select" group of less healthy patients who were eligible for Medicare for health reasons before they reached the age of 65 years. Finally, we were not able to measure and adjust for lifestyle variables such as smoking and body mass index directly; however, we adjusted for codes for tobacco use and chronic obstructive pulmonary disease as proxies for smoking. We also previously found that smoking and body mass index do not meaningfully affect the choice of initiation of DPP-4 inhibitors vs SUs and TZDs and therefore are unlikely to be confounders in this setting. 44 In summary, we did not observe an increased short-term risk of 
